linjc16/ctgov huggingface dataset:
Cosmic Weather and Cardiogenic Pulmonary Edema

Study Overview
=================
Brief Summary
-----------------
Retrospective clinical study to evaluate whether there is any correlation between the pre-hospital incidence of cardiogenic pulmonary oedema (CPE) in the selected region and the space weather parameters.

Detailed Description
-----------------
Emergency Medical Service of the Central Bohemian Region is the exclusive provider of primary pre-hospital emergency care in the Central Bohemian Region, Czech Republic. The region includes both the rural and urban population, in total of 1 315 299 inhabitants on a total area of 11 015 km2. A computer search of patients with dyspnoea between 1.10.2008 and 30.6.2014 will be conducted and all cases of cardiogenic pulmonary oedema will be selected. Physical parameters of space weather and geomagnetic field disturbances will be obtained from the database of Institute of Experimental Physics, Slovak Academy of Sciences, Slovak Republic. The datasets will be analysed whether there is any correlation between the pre-hospital incidence of CPE in the selected region and the parameters of space weather and geomagnetic field disturbances.

Official Title
-----------------
Impact of Cosmic Weather on Pre-hospital Incidence of Cardiogenic Pulmonary Edema

Conditions
-----------------
Pulmonary Edema Cardiac Cause

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients treated by Emergency Medical Service of the Central Bohemian Region for cardiogenic pulmonary edema between 1.10.2008 and 30.6.2014. Exclusion Criteria: Dyspnea from other cause than cardiogenic pulmonary edema.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CPE patients<br>All patients prehospitally treated for cardiogenic pulmonary edema in the pre-hospital emergency setting in the Central Bohemian region, Czech Republic. | Other: No intervention<br>* No intervention will be performed while it is retrospective observational study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Significant correlation between incidence of CPE and activity of the space weather | Significant correlation between incidence of CPE and activity of the space weather | 4 years | 
| Significant correlation between incidence of CPE and the degree of the geomagnetic field disturbance | Significant correlation between incidence of CPE and the degree of the geomagnetic field disturbance | 4 years |
An In Silico Trial to Evaluate Prospectively the Performance of a Radiomics Algorithm for UIP Compared to Medical Doctors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare AI performance to doctor's performance in the evaluation of IPF/UIP and ILDs without UIP(proven by biopsy).

Official Title
-----------------
An In Silico Trial to Evaluate Prospectively the Performance of a Radiomics Algorithm for UIP Compared to Medical Doctors

Conditions
-----------------
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Radiomics

Intervention / Treatment
-----------------
* Other: Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - the availability of non-contrast-enhanced HRCT Exclusion Criteria: the use of contrast enhancement images containing metal or motion artifacts Images reconstructed with a slice thickness larger than 1.5 mm
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IPF/UIP_CT based<br>patients with an ILD and a pathological UIP pattern and a final diagnosis of IPF | Other: Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern<br>* The aim is to evaluate the performance of AI with the performance of doctors<br>|
| IPF/UIP_Biopsy based<br>patients with a final diagnosis of IPF but a less typical HRCT pattern( lung biopsy required for the diagnosis) | Other: Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern<br>* The aim is to evaluate the performance of AI with the performance of doctors<br>|
| ILD but not IPF and prove by biopsy not UIP<br>patients with an ILD and a pathological non-UIP pattern | Other: Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern<br>* The aim is to evaluate the performance of AI with the performance of doctors<br>|
| Normal<br>Normal healthy patients | Other: Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern<br>* The aim is to evaluate the performance of AI with the performance of doctors<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The performance of Radiomics algorithm compared to the ground truth | Reporting the performance measure: accuracy | May 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparing the performance of the radiomics algorithm to that of physicians | Correctness of the diagnosis - the most probable thin-section pattern (dichotomous outcome: yes or no) | June 2021 |
HepQuant to Predict Hepatic Encephalopathy After TIPS

Study Overview
=================
Brief Summary
-----------------
A pilot study to determine if a simple blood test can predict patients at risk for significant episodes of confusion and disorientation that can occur in patients who receive an artificial shunt through the liver to control complications of liver disease.

Official Title
-----------------
HepQuant to Predict Hepatic Encephalopathy in Patients Who Receive Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Refractory Ascites - a Pilot Study

Conditions
-----------------
Hepatic Encephalopathy, Cirrhosis, Liver

Intervention / Treatment
-----------------
* Diagnostic Test: HepQuant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects over the age of 18 able to provide consent Subjects undergoing initial TIPS procedure for the primary indication of treatment of ascites Exclusion Criteria: Prisoners Pregnant women Subjects undergoing TIPS placement as part of an investigational study outside of usual clinical care Subjects taking beta-blocker medications or angiotensin converting enzyme inhibitors Subjects with evidence of porto-systemic shunts present on imaging (eg splenorenal shunt) Subjects with calculated MELD score >12 based on most recent laboratory values before consent Subjects with prior history of overt hepatic encephalopathy (grade 3-4) that was primary reason for hospitalization. Episodes of hepatic encephalopathy that were the consequence of other precipitating event (such as variceal bleeding or infection) will not be considered exclusionary. Subjects with a known sensitivity to albumin preparations, any ingredient in the formulation, or components of the container Subjects unable to fast for >5 hours prior to the HepQuant administration or subjects who are unable to drink the oral dose of the cholate ( 40mL of liquid).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HepQuant Testing<br> | Diagnostic Test: HepQuant<br>* Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Onset of Hepatic Encephalopathy |  | 6 months |
Effect of TyG Index on Outcomes of Radical Prostatectomy

Study Overview
=================
Brief Summary
-----------------
We investigate the association between Triglyserid-Glucose(TyG) index and prostate cancer in patients undergoing radical prostatectomy.

Detailed Description
-----------------
TyG index is calculated with special formula. Patients undergoing radical prostatectomy are divided two groups according to the cut-off level of 8.55 for TyG index.Groups were compared statistically in terms of oncological outcomes and survival.

Official Title
-----------------
A Novel Prognostic Risk Factor for Patients Undergoing Radical Prostatectomy: Triglyseride-Glucose (TyG) Index

Conditions
-----------------
Metabolic Syndrome, Prostate Cancer, Insulin Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing radical prostatectomy for prostate cancer Exclusion Criteria: taking medicines for established diabetes and dyslipidaemia, presence of endocrinological disease, history of bariatric surgery, missing data and patients with uncontrolled follow-up
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oncological outcomes | Effect of TyG index on oncological outcomes of Prostate cancer | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | Death date of patient after radical prostatectomy | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Triglyseride-Glucose index, prostate cancer, radical prostatectomy, metabolic syndrome
The Effect of Progesterone on Human Endometrium

Study Overview
=================
Brief Summary
-----------------
This study evaluates the relationship between progesterone levels and endometrial gene expression

Official Title
-----------------
The Effect of Progesterone Levels on Human Endometrial Transcriptomics During the Implantation Window

Conditions
-----------------
Fertility

Intervention / Treatment
-----------------
* Genetic: Microarray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 18-35, regular menstrual cycles, the cycle length between 25 and 35 days, body mass index (BMI) between 18 - 25 Exclusion Criteria: History of infertility, history of pelvic pain or/and endometriosis, history of pelvic mass, history of hormonal therapy in the last 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low progesterone<br>Women with progesterone level below 15 ng/ml | Genetic: Microarray<br>* High throughput technique for determining global gene expression of the condition of interest<br>|
| Normal progesterone<br>Women with progesterone level above 15 ng/ml | Genetic: Microarray<br>* High throughput technique for determining global gene expression of the condition of interest<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differentially expressed genes between women with low and normal progesterone | Fold-change and p-value were used to determine differentially expressed genes using Partek software | 2 months |
Therapeutic Swallow Sensor

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.

Detailed Description
-----------------
The project goal is the development and early stage validation of a wearable sensor for dysphagia in patients with PD. The first phase of the program involves engineering goals relating to increasing the battery life of this sensor to 48 hours between charges and reducing the overall form factor size. The second phase of the program is to conduct focus groups with PD patients to assess sensor usability, set up burden, and design feedback. The third phase of the study will assess the feasibility of the sensor to detect and cue swallowing in a small cohort of PD patients.

Official Title
-----------------
Novel Sensor for Swallowing in Patients With Parkinson's Disease

Conditions
-----------------
Dysphagia, Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥21 years of age PD patients of any severity Evidence of mild to moderate oropharyngeal dysphagia as determined by an SLP Exclusion Criteria: Patients cannot safely swallow at least one bolus of liquid without risk of aspiration End stage dementia

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent agreement with Gold Standard | Percent agreement between experimental sensor Gold standard (GS) respiratory inductance plethysmography (RIP) with Inductotrace System®, Ambulatory Monitoring) | 1 year |
Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral Nerve Excitability

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effect of intravenous ropivacaine and lidocaine on the receptive field of primary sensory afferents and their influence on the vascular bed. *Trial with medicinal product

Official Title
-----------------
Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: ropivacaine (Naropin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Male Age: 18 - 65 years Weight: 50-100kg Height: 155-195cm Signed and dated informed consent Sufficient command of German language Exclusion criteria: Contraindications to the class of drugs under study Vulnerable subjects (intellectually or mental impaired) Known hypersensitivity to class of drugs or the investigational product Drug abuse Known peripheral neuropathies Diabetes mellitus Chronic alcohol consumption Congestive heart disease Participants of other studies during study period Smoker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aera of flare reaction (cm2), area of primary and secondary hyperalgesia (cm2) |  | 1 year |
Bone Flap Osteomyelitis Following Craniectomy : Retrospective Evaluation of Clinical Presentation, Microbiological Diagnosis and Management

Study Overview
=================
Brief Summary
-----------------
Osteitis of the cranial flap after craniectomy is an unknown complex osteoarticular infection and there are few data concerning its epidemiology, its risk factors, and its management.

Official Title
-----------------
Bone Flap Osteomyelitis Following Craniectomy : Retrospective Evaluation of Clinical Presentation, Microbiological Diagnosis and Management

Conditions
-----------------
Osteitis, Cranial Flap

Intervention / Treatment
-----------------
* Other: patients having had an osteitis of the cranial flap after craniectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with cranial flap osteitis after craniectomy Patients who did not object to participating in the study Adult patients Exclusion Criteria: NA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients having had an osteitis of the cranial flap after craniectomy<br> | Other: patients having had an osteitis of the cranial flap after craniectomy<br>* description of management and failure of cranial flap after craniectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of cranial flap osteitis after craniectomy | proportion of patients | between 2010 and 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of failure in management of cranial flap osteitis after craniectomy | proportion of patients having a failure | between 2010 and 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteitis, cranial flap
Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.

Study Overview
=================
Brief Summary
-----------------
Comparison between FDG-PET and MRI for the assessment of response to intensive chemotherapy in multiple myeloma patients.

Detailed Description
-----------------
First whole body FDG-PET scan and MRI before the start of the treatment. Second whole body FDG-PET scan and MRI after the end of the treatment. On a basis of patient, comparison between PET and MRI will be done tumoral site by site. Sensitivity, Specificity will be estimated for both techniques. In case of discrepancy, another imaging method or biopsy (if easy to perform) will be serve as standard of reference. Kappa coefficients and Mc Nemar test will be performed to compare the two methods. FDG = fluorodeoxyglucose FLUCIS® (Schering-CisBio® international)

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Drug: FDG = fluorodeoxyglucose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients from 18 to 65 years old. De novo histologically proven multiple myeloma. Exclusion Criteria: No history of another cancer or of HIV No history of renal failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: FDG = fluorodeoxyglucose|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Ischemic Preconditioning and Thiol-disulfide Balance

Study Overview
=================
Brief Summary
-----------------
Various strategies have been proposed to prevent or mitigate the effects of ischemia-reperfusion injury following the use of tourniquets in orthopedic surgery cases. One of them is applying remote ischemic preconditioning. This randomized controlled trial is planned to evaluate the effectiveness of remote ischemic preconditioning in preventing tourniquet-induced ischemia-reperfusion injury in total knee arthroscopy with dynamic thiol-disulfide homeostasis.

Official Title
-----------------
Effect of Ischemic Preconditioning on Dynamic Thiol-disulfide Balance, Randomized Controlled Trial

Conditions
-----------------
Tourniquets

Intervention / Treatment
-----------------
* Other: Remote Ischemic Preconditioning
* Other: sham group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-III patients who will undergo total knee arthroplasty surgery under elective conditions Exclusion Criteria: emergency operation, Underlying neurological disorder, Underlying peripheral vascular disease, other types of concurrent surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Remote Ischaemic preconditioning (RIPC)<br>The group underwent Remote Ischemic Preconditioning. | Other: Remote Ischemic Preconditioning<br>* Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.<br>* Other names: RIPC group;|
| Sham Comparator: Sham Group<br>Sham control group without remote ischemic preconditioning | Other: sham group<br>* a deflated cuff placed on the upper arm for 30 min<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| thiol/disulfide homeostasis | Thiol/disulphide homeostasis will be determined at preoperatively and just before the tourniquet opened and at the 1st, 6th and 24th hours after the tourniquet is opened. | 24th hour after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thiol/disulfide homeostasis, ischemic preconditioning